Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT03386071
Status
No Longer Available

Conditions

  • Progressive Metastatic Castrate Resistant Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trametinib 2 mg — DRUG
    The dosage of trametinib for oral administration is 2mg once daily.

Study Details

The dosage of trametinib for oral administration is 2mg once daily. The patient is instructed to take the trametinib oncedaily dose at approximately the same time each day, by mouth with approximately 200 mL (almost 1 cup) of water on an empty stomach, either 1 hour before or 2 hours after a meal.

Key Dates

Status verified
Jan 2019

Related Studies